We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Weighs in on New Therapies for Multiple Myeloma, Favoring CAR-T Cell Options
ICER Weighs in on New Therapies for Multiple Myeloma, Favoring CAR-T Cell Options
The Institute for Clinical and Economic Review (ICER) has assessed the clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen for heavily pre-treated patients with triple-class refractory multiple myeloma who have completed many previous lines of therapy.